FDA Botanical Review Team To Implement Herbals Guidance, MaPP
This article was originally published in The Tan Sheet
Executive Summary
The newly formed Botanical Review Team in FDA's Office of New Drugs is intended to "consolidate OND's scientific and regulatory expertise in botanical products," according to a Feb. 20 agency announcement
You may also be interested in...
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA
FDA Botanical Drug Products Final Guidance Stresses Batch Consistency
An FDA final guidance on botanical drug products includes new language recommending that firms demonstrate "batch-to-batch consistency" for botanical drug candidates through the clinical development process prior to submitting an NDA